Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Internal Medicine
•
Myeloproliferative Neoplasms
•
Hematology
What aspirin dose do you favor for thrombotic prophylaxis in myeloproliferative neoplasms?
81 mg vs 162 mg
Answer from: at Academic Institution
I generally use 81 mg twice a day. If they have had a thrombotic event, or have microvascular symptoms, then I use 81 mg BiD.
Sign in or Register to read more
14664
Related Questions
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
Under which circumstances would you prefer ropeginterferon over hydroxyurea for patients with Polycythemia Vera?
In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?
For patients with essential thrombocythemia already on prophylactic dose DOACs, do you defer starting aspirin?
How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?
How would one approach concomitant diffuse large B cell lymphoma and fibrotic phase myelofibrosis?
For patients with essential thrombocythemia who develop venous thrombosis in the setting of elevated platelet counts, would you continue lifelong anticoagulation even after cytoreduction is achieved?
In which patient population diagnosed with CLL would you still treat with the FCR (fludarabine, cyclophosphamide, rituximab) regimen?
How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?